COX-2s, Statins Have No Class In USP Medicare Draft Formulary
U.S. Pharmacopeia has relegated some of the pharmaceutical industry's biggest blockbuster drug "classes" to the status of "recommended subdivisions" in its draft model Medicare formulary
U.S. Pharmacopeia has relegated some of the pharmaceutical industry's biggest blockbuster drug "classes" to the status of "recommended subdivisions" in its draft model Medicare formulary